{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:04:05Z","timestamp":1794499445606,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-61751-9","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T09:03:33Z","timestamp":1752483813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3993-6538","authenticated-orcid":false,"given":"Hannes","family":"Vietzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5830-9009","authenticated-orcid":false,"given":"Laura M.","family":"K\u00fchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-8245","authenticated-orcid":false,"given":"Sarah M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-1845","authenticated-orcid":false,"given":"Markus","family":"Ponleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pistorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-7147","authenticated-orcid":false,"given":"Christof","family":"Jungbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-1402","authenticated-orcid":false,"given":"Markus","family":"Reindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrieke","family":"Saucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Kauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rost\u00e1sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-5749","authenticated-orcid":false,"given":"Markus","family":"Breu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-1144","authenticated-orcid":false,"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-6647","authenticated-orcid":false,"given":"Paulus","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Puchhammer-St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"61751_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich, D. S., Lucchinetti, C. F. & Calabresi, P. A. Multiple sclerosis. N. Engl. J. Med 378, 169\u2013180 (2018).","journal-title":"N. Engl. J. Med"},{"key":"61751_CR2","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult. Scler. 26, 1816\u20131821 (2020).","journal-title":"Mult. Scler."},{"key":"61751_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Sci. (N. Y., NY) 375, 296\u2013301 (2022).","journal-title":"Sci. (N. Y., NY)"},{"key":"61751_CR4","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","volume":"286","author":"A Ascherio","year":"2001","unstructured":"Ascherio, A. et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. Jama 286, 3083\u20133088 (2001).","journal-title":"Jama"},{"key":"61751_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/jamaneurol.2024.0272","volume":"81","author":"M Cortese","year":"2024","unstructured":"Cortese, M. et al. Serologic response to the Epstein-Barr virus peptidome and the risk for multiple sclerosis. JAMA Neurol. 81, 515\u2013524 (2024).","journal-title":"JAMA Neurol."},{"key":"61751_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","volume":"21","author":"SS Soldan","year":"2023","unstructured":"Soldan, S. S. & Lieberman, P. M. Epstein-Barr virus and multiple sclerosis. Nat. Rev. Microbiol. 21, 51\u201364 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"61751_CR7","doi-asserted-by":"crossref","unstructured":"Vietzen H., et al. Accumulation of Epstein-Barr virus-induced cross-reactive immune responses is associated with multiple sclerosis. J. Clin. Invest. 134, e184481 (2024).","DOI":"10.1172\/JCI184481"},{"key":"61751_CR8","doi-asserted-by":"publisher","first-page":"16955","DOI":"10.1073\/pnas.1902623116","volume":"116","author":"K Tengvall","year":"2019","unstructured":"Tengvall, K. et al. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc. Natl. Acad. Sci. USA 116, 16955\u201316960 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61751_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321\u2013327 (2022).","journal-title":"Nature"},{"key":"61751_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3032","volume":"9","author":"OG Thomas","year":"2023","unstructured":"Thomas, O. G. et al. Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. Sci. Adv. 9, eadg3032 (2023).","journal-title":"Sci. Adv."},{"key":"61751_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1084\/jem.20072397","volume":"205","author":"JD L\u00fcnemann","year":"2008","unstructured":"L\u00fcnemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.  J. Exp. Med. 205, 1763\u20131773 (2008).","journal-title":"J. Exp. Med."},{"key":"61751_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250228","volume":"53","author":"AJ Gill","year":"2023","unstructured":"Gill, A. J., Schorr, E. M., Gadani, S. P. & Calabresi, P. A. Emerging imaging and liquid biomarkers in multiple sclerosis. Eur. J. Immunol. 53, 2250228 (2023).","journal-title":"Eur. J. Immunol."},{"key":"61751_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246\u2013257 (2022).","journal-title":"Lancet Neurol."},{"key":"61751_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier, S. et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 80, 287\u2013297 (2023).","journal-title":"JAMA Neurol."},{"key":"61751_CR15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","volume":"293","author":"LI Levin","year":"2005","unstructured":"Levin, L. I. et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496\u20132500 (2005).","journal-title":"JAMA"},{"key":"61751_CR16","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1212\/01.WNL.0000130496.51156.D7","volume":"62","author":"P Sundstr\u00f6m","year":"2004","unstructured":"Sundstr\u00f6m, P. et al. An altered immune response to Epstein-Barr virus in multiple sclerosis. Neurology 62, 2277\u20132282 (2004).","journal-title":"Neurology"},{"key":"61751_CR17","first-page":"325","volume":"95","author":"D Jons","year":"2024","unstructured":"Jons, D. et al. Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage. J. Neurol. Neurosurg. Psychiatry 95, 325\u2013332 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"61751_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1468-1331.2010.03083.x","volume":"17","author":"G Ingram","year":"2010","unstructured":"Ingram, G., Bugert, J. J., Loveless, S. & Robertson, N. P. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur. J. Neurol. 17, 1386\u20131389 (2010).","journal-title":"Eur. J. Neurol."},{"key":"61751_CR19","doi-asserted-by":"crossref","unstructured":"Rommer P. S., et al. Relapsing and progressive MS: the sex-specific perspective. Ther. Adv. Neurol. Disord. 13, 1756286420956495 (2020).","DOI":"10.1177\/1756286420956495"},{"key":"61751_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","volume":"5","author":"SM Orton","year":"2006","unstructured":"Orton, S. M. et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5, 932\u2013936 (2006).","journal-title":"Lancet Neurol."},{"key":"61751_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41582-024-01042-x","volume":"21","author":"C Nesbitt","year":"2025","unstructured":"Nesbitt, C., Van Der Walt, A., Butzkueven, H., Cheung, A. S. & Jokubaitis, V. G. Exploring the role of sex hormones and gender diversity in multiple sclerosis. Nat. Rev. Neurol. 21, 48\u201362 (2025).","journal-title":"Nat. Rev. Neurol."},{"key":"61751_CR22","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41591-024-02938-3","volume":"30","author":"CR Zamecnik","year":"2024","unstructured":"Zamecnik, C. R. et al. An autoantibody signature predictive for multiple sclerosis. Nat. Med 30, 1300\u20131308 (2024).","journal-title":"Nat. Med"},{"key":"61751_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/jnnp-2020-322941","volume":"91","author":"S Abrahamyan","year":"2020","unstructured":"Abrahamyan, S. et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 91, 681\u2013686 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"61751_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991662","volume":"13","author":"MI Dom\u00ednguez-Mozo","year":"2022","unstructured":"Dom\u00ednguez-Mozo, M. I. et al. Epstein-Barr virus and multiple sclerosis in a Spanish cohort: a two-years longitudinal study. Front Immunol. 13, 991662 (2022).","journal-title":"Front Immunol."},{"key":"61751_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/ana.26062","volume":"89","author":"B Nourbakhsh","year":"2021","unstructured":"Nourbakhsh, B. et al. Multiple Sclerosis is rare in Epstein-Barr virus-seronegative children with central nervous system inflammatory demyelination. Ann. Neurol. 89, 1234\u20131239 (2021).","journal-title":"Ann. Neurol."},{"key":"61751_CR26","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1212\/01.wnl.0000247665.94088.8d","volume":"67","author":"D Pohl","year":"2006","unstructured":"Pohl, D. et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67, 2063\u20132065 (2006).","journal-title":"Neurology"},{"key":"61751_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1474-4422(22)00471-9","volume":"22","author":"F Aloisi","year":"2023","unstructured":"Aloisi, F., Giovannoni, G. & Salvetti, M. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy.  Lancet Neurol. 22, 338\u2013349 (2023).","journal-title":"Lancet Neurol."},{"key":"61751_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","volume":"73","author":"RA Farrell","year":"2009","unstructured":"Farrell, R. A. et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73, 32\u201338 (2009).","journal-title":"Neurology"},{"key":"61751_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S1474-4422(23)00281-8","volume":"22","author":"C Lebrun-Frenay","year":"2023","unstructured":"Lebrun-Frenay, C. et al. Radiologically isolated syndrome. Lancet Neurol. 22, 1075\u20131086 (2023).","journal-title":"Lancet Neurol."},{"key":"61751_CR30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","volume":"80","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay, C. et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial. JAMA Neurol. 80, 1080\u20131088 (2023).","journal-title":"JAMA Neurol."},{"key":"61751_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"61751_CR32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/ene.14705","volume":"28","author":"G Bsteh","year":"2021","unstructured":"Bsteh, G. et al. Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. Eur. J. Neurol. 28, 1609\u20131616 (2021).","journal-title":"Eur. J. Neurol."},{"key":"61751_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209752","volume":"103","author":"G Bsteh","year":"2024","unstructured":"Bsteh, G. et al. Association of disease-modifying treatment with outcome in patients with relapsing multiple sclerosis and isolated MRI activity. Neurology 103, e209752 (2024).","journal-title":"Neurology"},{"key":"61751_CR34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1177\/13524585221081090","volume":"28","author":"E-M Wendel","year":"2022","unstructured":"Wendel, E.-M. et al. Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome. Mult. Scler. J. 28, 1553\u20131561 (2022).","journal-title":"Mult. Scler. J."},{"key":"61751_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejpn.2020.04.002","volume":"27","author":"EM Wendel","year":"2020","unstructured":"Wendel, E. M. et al. High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur. J. Paediatr. Neurol. 27, 86\u201393 (2020).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"61751_CR36","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","volume":"186","author":"H Vietzen","year":"2023","unstructured":"Vietzen, H. et al. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell 186, 5705\u20135718.e5713 (2023).","journal-title":"Cell"},{"key":"61751_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90639-z","volume":"11","author":"P Altmann","year":"2021","unstructured":"Altmann, P. et al. Seven day pre-analytical stability of serum and plasma neurofilament light chain. Sci. Rep. 11, 11034 (2021).","journal-title":"Sci. Rep."},{"key":"61751_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","volume":"221","author":"A Frey","year":"1998","unstructured":"Frey, A., Di Canzio, J. & Zurakowski, D. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221, 35\u201341 (1998).","journal-title":"J. Immunol. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61751-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:24:59Z","timestamp":1757222699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61751-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61751"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61751-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6416"}}